PMID- 19217856 OWN - NLM STAT- MEDLINE DCOM- 20090323 LR - 20220309 IS - 1542-0086 (Electronic) IS - 0006-3495 (Print) IS - 0006-3495 (Linking) VI - 96 IP - 4 DP - 2009 Feb 18 TI - Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. PG - 1388-98 LID - 10.1016/j.bpj.2008.10.042 [doi] AB - Doxorubicin (DOX) is used for treating various cancers. Its clinical use is, however, limited by its dose-limiting cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy still remains unknown. The goals were to investigate the molecular mechanism of DOX-induced cardiomyopathy and cardioprotection by mitoquinone (Mito-Q), a triphenylphosphonium-conjugated analog of coenzyme Q, using a rat model. Rats were treated with DOX, Mito-Q, and DOX plus Mito-Q for 12 weeks. The left ventricular function as measured by two-dimensional echocardiography decreased in DOX-treated rats but was preserved during Mito-Q plus DOX treatment. Using low-temperature ex vivo electron paramagnetic resonance (EPR), a time-dependent decrease in heme signal was detected in heart tissues isolated from rats administered with a cumulative dose of DOX. DOX attenuated the EPR signals characteristic of the exchange interaction between cytochrome c oxidase (CcO)-Fe(III) heme a3 and CuB. DOX and Mito-Q together restored these EPR signals and the CcO activity in heart tissues. DOX strongly downregulated the stable expression of the CcO subunits II and Va and had a slight inhibitory effect on CcO subunit I gene expression. Mito-Q restored CcO subunit II and Va expressions in DOX-treated rats. These results suggest a novel cardioprotection mechanism by Mito-Q during DOX-induced cardiomyopathy involving CcO. FAU - Chandran, Karunakaran AU - Chandran K AD - Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. FAU - Aggarwal, Deepika AU - Aggarwal D FAU - Migrino, Raymond Q AU - Migrino RQ FAU - Joseph, Joy AU - Joseph J FAU - McAllister, Donna AU - McAllister D FAU - Konorev, Eugene A AU - Konorev EA FAU - Antholine, William E AU - Antholine WE FAU - Zielonka, Jacek AU - Zielonka J FAU - Srinivasan, Satish AU - Srinivasan S FAU - Avadhani, Narayan G AU - Avadhani NG FAU - Kalyanaraman, B AU - Kalyanaraman B LA - eng GR - R01 CA077822/CA/NCI NIH HHS/United States GR - R01 HL073056/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Biophys J JT - Biophysical journal JID - 0370626 RN - 0 (Cardiotonic Agents) RN - 0 (Organophosphorus Compounds) RN - 1339-63-5 (Ubiquinone) RN - 42VZT0U6YR (Heme) RN - 47BYS17IY0 (mitoquinone) RN - 80168379AG (Doxorubicin) RN - EC 1.9.3.1 (Electron Transport Complex IV) SB - IM MH - Animals MH - Apoptosis/drug effects MH - Body Weight/drug effects MH - Cardiomyopathies/chemically induced/*drug therapy/physiopathology MH - Cardiotonic Agents/*pharmacology/therapeutic use MH - Doxorubicin/*pharmacology/toxicity MH - Electron Spin Resonance Spectroscopy MH - Electron Transport Complex IV/*metabolism MH - Endomyocardial Fibrosis/drug therapy MH - Heart/drug effects/physiology MH - Heme/physiology MH - Male MH - Mitochondria, Heart/drug effects/enzymology MH - Myocardium/*enzymology MH - Organophosphorus Compounds/*pharmacology/therapeutic use MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - Ubiquinone/*pharmacology/therapeutic use PMC - PMC2717244 EDAT- 2009/02/17 09:00 MHDA- 2009/03/24 09:00 PMCR- 2010/02/18 CRDT- 2009/02/17 09:00 PHST- 2008/08/11 00:00 [received] PHST- 2008/10/09 00:00 [accepted] PHST- 2009/02/17 09:00 [entrez] PHST- 2009/02/17 09:00 [pubmed] PHST- 2009/03/24 09:00 [medline] PHST- 2010/02/18 00:00 [pmc-release] AID - S0006-3495(08)00128-8 [pii] AID - BPJ114 [pii] AID - 10.1016/j.bpj.2008.10.042 [doi] PST - ppublish SO - Biophys J. 2009 Feb 18;96(4):1388-98. doi: 10.1016/j.bpj.2008.10.042.